Search Results - "Canioni, D."

Systemic mastocytosis and bone involvement in a cohort of 75 patients by Barete, S, Assous, N, de Gennes, C, Grandpeix, C, Feger, F, Palmerini, F, Dubreuil, P, Arock, M, Roux, C, Launay, J M, Fraitag, S, Canioni, D, Billemont, B, Suarez, F, Lanternier, F, Lortholary, O, Hermine, O, Francès, C

“…To investigate bone involvement in a large cohort of systemic mastocytosis (SM) patients, and evaluate the efficacy of bisphosphonate therapy. From 2000 to…”
Get more information

From hepatitis C virus infection to B-cell lymphoma by Couronné, L., Bachy, E., Roulland, S., Nadel, B., Davi, F., Armand, M., Canioni, D., Michot, J.M., Visco, C., Arcaini, L., Besson, C., Hermine, O.

“…In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL),…”
Get full text

The efficacy of exclusive nutritional therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding by Rubio, A., Pigneur, B., Garnier‐Lengliné, H., Talbotec, C., Schmitz, J., Canioni, D., Goulet, O., Ruemmele, F. M.

“…Summary Background  Nutritional therapy has an established role as induction therapy in paediatric Crohn’s disease. However, compliance is the main difficulty…”
Get full text

Assessment and outcome of children with intestinal failure referred for intestinal transplantation by Ganousse-Mazeron, S, Lacaille, F, Colomb-Jung, V, Talbotec, C, Ruemmele, F, Sauvat, F, Chardot, C, Canioni, D, Jan, D, Revillon, Y, Goulet, O

“…Summary Background & aims Chronic intestinal failure (CIF) requires long term parenteral nutrition (PN) and, in some patients, intestinal transplantation…”
Get full text

The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis by Polivka, L., Parietti, V., Bruneau, J., Soucie, E., Madrange, M., Bayard, E., Rignault, R., Canioni, D., Fraitag, S., Lhermitte, L., Feroul, M., Tissandier, M., Rossignol, J., Frenzel, L., Cagnard, N., Meni, C., Bouktit, H., Collange, A.-F., Gougoula, C., Parisot, M., Bader-Meunier, B., Livideanu, C., Laurent, C., Arock, M., Hadj-Rabia, S., Rüther, U., Dubreuil, P., Bodemer, C., Hermine, O., Maouche-Chrétien, L.

“…Mastocytosis is a heterogeneous disease characterized by an abnormal accumulation of mast cells (MCs) in 1 or several organs. Although a somatic KIT D816V…”
Get full text

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial by Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Salles, G.A., Gaulard, P., Tilly, H., Jais, J.P., Molina, T.J.

“…Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk…”
Get full text

CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological and histopathological analysis of 27 patients by Poirier, E., Fraitag, S., Tezenas du Montcel, S., Moguelet, P., Charlotte, F., Lortholary, O., Hermine, O., Canioni, D., Barete, S.

Get full text

Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 by EVANS, P. A. S, POTT, Ch, SCHUURING, E, SPAARJAREN, M, BOONE, E, GONZALEZ, D, MARTINEZ, B, VILLUENDAS, R, GAMEIRO, P, DISS, T. C, MILLS, K, MORGAN, G. J, GROENEN, P. J. T. A, CARTER, G. I, MILNER, B. J, PEARSON, D, HUMMEL, M, JUNG, W, OTT, M, CANIONI, D, BELDJORD, K, BASTARD, C, DELFAU-LARUE, M. H, SALLES, G, VAN DONGEN, J. J. M, MOLINA, T. J, CABEYADAS, J, DAVI, F, BERGER, F, GARCIA, J. F, VAN KRIEKEN, J. H. J. M, PALS, S, KLUIN, Ph

“…Polymerase chain reaction (PCR) assessment of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is an important diagnostic tool in…”
Get full text

Impacts of donor‐specific anti‐HLA antibodies and antibody‐mediated rejection on outcomes after intestinal transplantation in children by Petit, L.‐M., Rabant, M., Canioni, D., Suberbielle‐Boissel, C., Goulet, O., Chardot, C., Lacaille, F.

“…AMR is a risk factor for graft failure after SBTx. We studied impact of DSAs and AMR in 22 children transplanted between 2008 and 2012 (11 isolated SBTx, 10…”
Get full text

HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY by Cheminant, M., Burroni, B., Le Bris, Y., Chartier, L., Oberic, L., Ribrag, V., Delfau, M.‐H., Thieblemont, C., Gressin, R., Canioni, D., Peyre, M., Laurent, C., Steimle, T., Kaltenbach, S., Asnafi, V., Macintyre, E., Callanan, M., Le Gouill, S., Hermine, O.

Get full text

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study by Djelbani-Ahmed, S., Chandesris, M. O., Mekinian, A., Canioni, D., Brouzes, C., Hanssens, K., Pop, G., Durieu, I., Durupt, S., Grosbois, B., Besnard, S., Tournilhac, O., Beyne-Rauzy, O., Agapé, P., Delmer, A., Ranta, D., Jeandel, P. Y., Georgin-Lavialle, S., Frenzel, L., Damaj, G., Eder, V., Lortholary, O., Hermine, O., Fain, O., Soussan, M.

“…Introduction Mastocytosis is a clonal haematological disease characterized by uncontrolled proliferation and the activation of mast cells. The value of…”
Get full text

CLINICO‐BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY by Baldacini, M., Burroni, B., Le Gouill, S., Gressin, R., Hermine, O., Traverse‐glehen, A., Martin, A., Moreau, A., Bene, M., Fogarty, P., Canioni, D., Fornecker, L.

Get full text

Long-term outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation by Lacaille, F, Vass, N, Sauvat, F, Canioni, D, Colomb, V, Talbotec, C, De Serre, N Patey-Mariaud, Salomon, J, Hugot, J-P, Cézard, J-P, Révillon, Y, Ruemmele, F M, Goulet, O

“…Small bowel (SB) transplantation (Tx), long considered a rescue therapy for patients with intestinal failure, is now a well recognised alternative treatment…”
Get more information

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY by Le Gouill, S., Beldi‐Ferchiou, A., Cacheux, V., Salles, G., Canioni, D., Bodet‐Milin, C., Alcantara, M., Delwail, V., Gastinne, T., Thieblemont, C., Maisonneuve, H., Lamy de la Chapelle, T., Oberic, l., Bouabdallah, K., Ribrag, V., Delfau‐Larue, M., Macintyre, E., Hermine, O.

Get full text

REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE by Bossard, C., Laghmari, O., Le Bris, Y., Bonnet, A., Moreau, A., El Alami Thomas, W., Pavageau, A., Guerzider, P., Maisonneuve, H., Ruminy, P., Bene, M., Casasnovas, O., Canioni, D., Thieblemont, C., Petrella, T., Jardin, F., Salles, G., Tilly, H., Gaulard, P., Haioun, C., Brière, J., Le Gouill, S., Copie Bergman, C., Molina, T.J.

Get full text

Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms by Georgin‐Lavialle, S., Launay, J.‐M., Côté, F., Soucié, E., Soria, A., Damaj, G., Moura, D. S., Canioni, D., Hanssens, K., Chandesris, M.‐O., Barète, S., Dubreuil, P., Lortholary, O., Hermine, O., Sokol, H.

“…The main metabolism pathway of tryptophan is protein formation, but it can also be metabolized into serotonin and kynurenine. Indoleamine 2,3‐dioxygenase (IDO)…”
Get full text

Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades by Michonneau, David, Suarez, Felipe, Lambert, Jérôme, Adam, Julien, Brousse, Nicole, Canioni, Danielle, Anglicheau, Dany, Martinez, Frank, Snanoudj, Renaud, Legendre, Christophe, Hermine, Olivier, Mamzer-Bruneel, Marie-France

“…Late-onset post-transplantation lymphoproliferative disorders (PTLDs) occur 1 year after transplantation and are associated with poor prognosis. Initial…”
Get full text

PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL by Canioni, D., Brice, P., Bologna, S., Voillat, L., Gabarre, J., Casasnovas, O., Devidas, A., Coiffier, B., Aoudjhane, A., Audouy, B., Andre, M., Fortpied, C., Carde, P., Mounier, N., Briere, J.

Get full text

Evaluation of C4d Deposition and Circulating Antibody in Small Bowel Transplantation by De Serre, N. Patey‐Mariaud, Canioni, D., Lacaille, F., Talbotec, C., Dion, D., Brousse, N., Goulet, O.

“…Antibody‐mediated rejection (AMR) consensus criteria are defined in kidney and heart transplantation by histological changes, circulating donor‐specific…”
Get full text

Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas by Larousserie, F, Bardel, E, Coulomb L'Herminé, A, Canioni, D, Brousse, N, Kastelein, RA, Devergne, O

“…Epstein–Barr virus (EBV)‐induced gene 3 (EBI3) is expressed by tumour cells in several EBV‐associated malignancies. EBI3 was recently found to associate with a…”
Get full text